CARL – carlsmed, inc. (US:NASDAQ)

News

Carlsmed (CARL) had its price target lowered by The Goldman Sachs Group, Inc. from $19.00 to $17.00. They now have a "buy" rating on the stock.
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
Carlsmed (CARL) was upgraded by Zacks Research from "strong sell" to "hold".
Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference [Yahoo! Finance]
Carlsmed (CARL) was downgraded by Zacks Research from "hold" to "strong sell".
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com